Musli Thyropeutics
Slowing Cancer Progression via the Thyroid Gland
Company Overview
Snapshot
Founded in November 2011 by Offer Fabian and Osnat Ashur-Fabian, Musli Thyropeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage. In November 2016, Musli Thyropeutics initiated a clinical study to evaluate the induction of hypothyroxinemia as an adjunct to conventional therapies in glioblastoma multiforme patients.
Business overview
Musli Thyropeutics is a Health Tech & Life Sciences company focused on developing treatments to slow and inhibit cancer progression. Its core technology involves inducing hypofunction of the thyroid gland to enhance the efficacy of chemotherapy and radiotherapy. The company serves the healthcare and life sciences sectors, targeting providers, patients, and pharmaceutical industries with its drug discovery and development efforts, particularly in cancer treatments.
Strategic signal
In November 2016, Musli Thyropeutics announced a clinical study (NCT02654041) to investigate the induction of hypothyroxinemia as an adjunct to conventional therapies for glioblastoma multiforme patients. This signals the company's commitment to advancing its therapeutic approach through clinical validation, which is a critical step for investor confidence and potential market adoption in the oncology space.
Log in to access full profile ›Company Intelligence Q&A
- What is Musli Thyropeutics' primary focus?
- Musli Thyropeutics focuses on developing treatments to slow and inhibit cancer progression by inducing hypofunction of the thyroid gland, aiming to enhance the efficacy of chemotherapy and radiotherapy.
- When was Musli Thyropeutics founded and by whom?
- Musli Thyropeutics was founded in November 2011 by Offer Fabian and Osnat Ashur-Fabian.
- What was a significant clinical development for Musli Thyropeutics?
- In November 2016, Musli Thyropeutics initiated a clinical study to evaluate the induction of hypothyroxinemia as an adjunct to conventional therapies in glioblastoma multiforme patients.
- What is the current operational status of Musli Thyropeutics?
- Musli Thyropeutics is currently non-active, having ceased to operate in December 2021.
- Which markets does Musli Thyropeutics target?
- Musli Thyropeutics targets the United States market with its cancer treatment solutions.